^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Opaxio (paclitaxel poliglumex)

    i
    Other names: CT-2103, CHC 12103, CHC12103, PPX, CT 2103, PG-TXL
    Associations

    News

    Trials
    Company:
    SOBI
    Drug class:
    Bcl2 inhibitor, Tubulin inhibitor
    Related drugs:
    Associations

    News

    Trials
    3years
    A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer (clinicaltrials.gov)
    P1/2, N=53, Completed, State University of New York - Upstate Medical University | Recruiting --> Completed
    Trial completion
    |
    ER (Estrogen receptor)
    |
    ER expression
    |
    Erbitux (cetuximab) • Opaxio (paclitaxel poliglumex)